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Introduction {#sec001}
============

Acute lymphoblastic leukemia (ALL) is the most common cancer during childhood. Different clinical, immunophenotypic and molecular subtypes have been described for the disease \[[@pone.0227314.ref001]\]. In contrast to other cancers, ALL has reached cure rates around 90% in developed countries as a result of the improvement in chemotherapy treatments based on a prognostic stratification. Among prognostic features, the age and white blood cell count (WBC) are the most consistently used across chemotherapy protocols \[[@pone.0227314.ref002]\].

Mexico City has one of the highest incidence rates of childhood leukemia worldwide with 49.5 cases per million children under the age of 15, which is similar to that reported for Hispanic populations living in the United States \[[@pone.0227314.ref003]--[@pone.0227314.ref005]\]. In addition, the Hispanic population not only has the highest incidence rates in ALL, but also one of the lowest survival rates within the United States, so that the ethnic and racial disparities are also considered as important factors that influence both the incidence and the efficacy of the treatment for this cancer \[[@pone.0227314.ref006]\]. In previous studies, it has been reported that there are differences in the clinical characteristics at diagnosis of Mexican patients with ALL in comparison to children from other populations where survival rates are better. For instance, almost 50% of ALL Mexican children are classified as having high risk of relapse according to the National Cancer Institute (NCI) criteria based on patient´s age and WBC count at diagnosis, whereas in developed countries, only one third of patients are classified as having a high risk of relapse using the same criteria \[[@pone.0227314.ref007], [@pone.0227314.ref008]\].

Furthermore, despite the use of the same chemotherapy regimens, in the last years it has been reported an upward trend since the incidence, relapses and mortality rates for Mexican children with ALL occur at a frequency of three times higher in comparison to that reported for children from developed countries \[[@pone.0227314.ref007]\]. Therefore, the identification of novel risk factors associated with ALL and the development of new therapeutic targets become extremely necessary for high risk populations.

As other cancers, ALL seems to be originated by multifactorial causes including both genetic and environmental. In the last decade, immune response has been demonstrated to play an essential role in the recognition and killing of cancer cells \[[@pone.0227314.ref009]\]. T lymphocytes along NK cells are immune cells that seem to dominate the immune response against leukemia \[[@pone.0227314.ref010]\]. Consequently, the important role of NK cells has been clearly demonstrated in the treatment of high risk leukemia \[[@pone.0227314.ref011]\]. Additional evidence has arisen from studies conducted in high-risk pediatric ALL patients undergoing hematopoietic stem cell transplantation (HSCT), showing the importance of selecting donors with allogenic NK cells to successfully cure patients \[[@pone.0227314.ref012], [@pone.0227314.ref013]\]. In contrast, an impaired NK cell-mediated cytotoxicity and/or abnormal expression of surface receptors has been observed in patients suffering from leukemia \[[@pone.0227314.ref014]--[@pone.0227314.ref016]\]. Notwithstanding, the studies have been conducted mostly in patients with chronic or myeloid leukemias \[[@pone.0227314.ref017]--[@pone.0227314.ref019]\]. A previous study has reported that peripheral blood NK cells from B-ALL patients have a compromised cytotoxicity towards K562 and autologous blasts. In addition, cell surface expression of NKp46 and NKG2A were altered in NK cells from B-ALL patients regarding age-matched healthy controls \[[@pone.0227314.ref020]\]. In the same study, Rouce and collaborators showed that after leukemia remission, NK cell-mediated cytotoxicity is recovered towards K562 but no towards autologous blast, indicating that blast undergo successful immune editing resulting in the selection of blast that avoid NK cell effector responses \[[@pone.0227314.ref020]\]. A recent investigation has suggested that a low NK cell production in bone marrow from patients suffering from ALL may contribute in disease progression. Moreover, an increase in the percentages of NK cells expressing class I restricted T-cell associated molecule (CRTAM) may be also associated with suppressor properties favoring malignant progression \[[@pone.0227314.ref021]\].

NK cells play an essential role in killing unwanted cells such as cancer and virus-infected cells. Unlike T and B lymphocytes, whereas antigen receptors dominate effector functions, NK cells express various germ-line encoding receptors that either activate or inhibit NK cell-mediated lysis of target cells \[[@pone.0227314.ref022]\]. A delicate balance between the signals emanating from activation and inhibition receptors dictate the outcome \[[@pone.0227314.ref023]\]. A major group of receptors influencing NK cell effector functions are those belonging to Killer cell immunoglobulin-like receptors (KIR) family. By recognizing MHC-I molecules on target cells, members of this family can either activate or inhibit NK cell function. Interestingly, an important association between a particular *KIR* genotype and an increased risk of leukemia has been reported \[[@pone.0227314.ref024]\]. Moreover, this association was more pronounced in Hispanic patients. Besides surface receptors, NK cells express an important number of signaling proteins including adapters and enzymes. Whereas genetic evidence has shown redundancy in signaling proteins governing NK cell-mediated effector functions \[[@pone.0227314.ref025]\], recent studies have led us to appreciate a unique role for a family of adapter proteins named signaling lymphocytic activation molecule (SLAM)-associated protein (SAP)-related adaptors \[[@pone.0227314.ref026], [@pone.0227314.ref027]\]. The SAP family of adapters are signaling proteins that play an essential role in dictate NK cell responsiveness \[[@pone.0227314.ref028], [@pone.0227314.ref029]\]. This family is composed by three members named SAP, EAT-2 (Ewing's sarcoma-associated transcript 2) and ERT (EAT-2-related transducer, only in mouse). By mean of their SH2 domains, members of this family are able to interact with the immunoreceptor tyrosine-based switch motif (ITSMs) domains presents in the cytoplasmic region of the SLAM family of receptors \[[@pone.0227314.ref030]\]. Mouse models have shown that NK cells from mice lacking either SAP o simultaneously SAP, EAT-2 and ERT are unresponsive towards hematopoietic target cells whereas maintain responsiveness towards non-hematopoietic target cells \[[@pone.0227314.ref026]\]. These studies indicate the important role of SAP family proteins in governing NK cell-mediated cytotoxicity towards hematopoietic cells including malignancies. At present is unknown whether an altered expression of members of the SAP family in NK cells is associated with NK cell dysfunction favoring the emergence of hematological malignancies.

The aim of the present study was to perform a phenotypic, based on SAP expression, and a functional characterization, based on lysis of K562, of NK cells from children with high incidence for ALL at the moment of diagnosis and before treatment initiation.

Material and methods {#sec002}
====================

Patients {#sec003}
--------

The Mexican Inter-Institutional Group for identifying childhood leukemia causes (MIGICCL) conducted a case-control study. 41 cases were patients aged under 17 years diagnosed with ALL between July 1, 2016 and January 31, 2017, and treated in Mexico City public hospitals. Diagnosis of ALL was based on the morphologic and immunophenotypic features of leukemic cells. Peripheral blood samples (2--3 ml) from patients were obtained at the moment of diagnosis and before treatment initiation. 14 healthy controls were selected from the same health institution that referred the children with leukemia. The controls were children without leukemia matched with cases regarding age and sex. Children with the following diagnoses were not invited to participate: neoplasms, hematological diseases, allergies, infections, and congenital malformations. The main diagnoses of the controls were open fractures, hernias, orchidopexy, tonsillectomy, and other benign surgical diseases. Blood samples from the control group were taken at the time the patient was punctured before starting anesthesia and the surgical procedure.

Clinical data collection and risk classification {#sec004}
------------------------------------------------

Information regarding gender; age at diagnosis; white blood cell count (WBC); immunophenotype; dates of ALL diagnosis, treatment initiation, last visit, death, relapse, was collected from the patients' clinical charts.

Risk classification at the moment of diagnosis was based on the National Cancer Institute \[[@pone.0227314.ref031]\] risk criteria. Patients between 1 and 10 years old and a leukocyte count \<50 x 109/L were classified as NCI standard-risk whereas those aged ≥10 years or a leukocyte count ≥50 x 109/L were classified as NCI high-risk. All patients were treated according to the chemotherapy protocol used in the hospital where they received medical care.

Approval by National Scientific Research and Ethics Committee was obtained with the number R-2016-785-042. Furthermore, written informed consent was obtained from child´s parents and assent from patients ≥8 years of age.

NK cell phenotyping {#sec005}
-------------------

Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll density separation (GE healthcare, Life Systems). For the evaluation of intracellular expression of SAP in NK cells, the PBMCs were stained with the following panel of fluorochrome-conjugated monoclonal Abs directed against cell surface markers: CD3 FITC (Biolegend, clone OKT3), CD56 APC (Biolegend, clone 5.1H11). Then, cells were fixed and permeabilized using Cytofix/Cytoperm Kit (BD Bioscience) and finally stained using the murine PE conjugated monoclonal antibody directed against human SAP (Thermo Scietific, clone XLP 1D12). An isotype control was used for every staining. Flow cytometric data were acquired on FACSCanto II (BD bioscience) and analyses with the use of FlowJo 7.6.5 software (Tree Star, Ashland, OR). Gates were set to exclude CD3^+^lymphocytes. Thereafter, NK cells were defined by the expression of CD56. The MFI SAP expression in NK cells was determined by using isotype control. SAP expression was analyzed in 18 B-ALL patients and 14 age-matched healthy controls.

NK cell degranulation assays {#sec006}
----------------------------

NK cell degranulation assays were performed as previously described \[[@pone.0227314.ref032]--[@pone.0227314.ref034]\]. Briefly, PBMCs (1x10^6^/ml) were incubated with K562 cells (2x10^6^/ml) in a total volume of 200 ul in a 96 well plate. After 4 hours of incubation at 37°C, cells were recovered and stained using following antobodies: anti-CD3 FITC, anti-CD56 APC, and anti-CD107 PE (Biolegend, clone H4A3). GolgiStop was not included in these assays. Cells were acquired on FACSCanto II (BD bioscience) and analyses with the use of FlowJo 7.6.5 software (Tree Star, Ashland, OR). Gates were set to exclude CD3^+^ lymphocytes. Thereafter, the percentage of cells positive for CD107a was obtained after gating in CD3^-^CD56^+^ lymphocytes. The basal percentages for CD107a were obtained from PBMCs incubated alone. Degranulation was represented as ΔCD107a, which is the difference between the percentage of NK cells expressing surface CD107a after K562 stimulation and the percentage of NK cells expressing surface CD107a after incubation with medium alone. NK cell degranulation assays were performed in 41 acute leukemia patients and 14 age-matched healthy controls.

Statistical analysis {#sec007}
--------------------

Statistical analyses were performed by using SPSS IBM (Statistical Package for the Social Sciences, Inc., Version 21, Chicago, IL, USA). U-Mann Whitney Test was used to compare differences regarding phenotypic and functional features between cases and controls and disease subtypes and clinical subgroups (high vs. standard risk, WBC \<50,000 and ≥50,000).

Results {#sec008}
=======

Study population {#sec009}
----------------

Samples of 41 patients with ALL were included in the present analysis. The median age of patients was 11 years (range: 2--16 years). Of these, 35 corresponded to B-ALL, and 6 to T-ALL. There was a slight predominance of males (53.6%; n = 22). According to NCI risk classification criteria, 27 patients (65.8%) were high-risk patients. NK cell degranulation analysis was performed in a total of 41 ALL patients, whereas the assays for SAP expression and NK cell degranulation on same sample was possible to be conducted only in 18 patients. All data were compared with age-matched controls.

Abnormal NK cell percentages in pediatric ALL patients {#sec010}
------------------------------------------------------

It has been reported that patients suffering from leukemia have abnormal percentages and absolute numbers of NK cells at moment of diagnosis \[[@pone.0227314.ref035], [@pone.0227314.ref036]\]. Therefore, we decide to evaluate the percentages of NK cells in pediatric patients suffering from ALL. In our study, at moment of diagnosis, we found a significant difference in the percentages of NK cells in ALL patients compared to age-matched controls as previously reported ([Fig 1A and 1B](#pone.0227314.g001){ref-type="fig"}). Moreover, a significant difference was also observed in pre-B-ALL patients compared to T-ALL patients, where those with T-ALL displayed the lowest percentages ([Fig 1C](#pone.0227314.g001){ref-type="fig"}). Interestingly, when ALL patients were stratified according to age as risk factor, the percentages of NK cells in ALL patients between 1 and 9 years of age were significantly lower compared to ALL patients aged 10 years or older ([Fig 1D](#pone.0227314.g001){ref-type="fig"}). These data suggest that the percentages of peripheral blood NK cells are lower in ALL patients.

![NK cell percentages are abnormal in pediatric ALL patients.\
A) Gating strategy to obtain NK cell percentages and representative FACS plots. NK cells from pediatric patients or healthy controls were defined by gating on the CD3-CD56+ lymphocyte fraction of PBMCs. B) The Percentages of NK cells in the lymphocyte gates were analyzed in 41 patients with ALL at moment of diagnosis compared to 14 healthy age-matched controls. C) Percentages of NK cells were analyzed according to immunophenotype in 30 pre-B-ALL patients and 6 T-All patients. D) Percentages of NK cells were analyzed according to age in 30 pre-B-ALL patients compared to 14 age-matched controls. Error bars denote standard error of the mean between individuals within group. P values report significance according to U-Mann Whitney Test one-tail. All data were acquired on FACSCanto II (BD bioscience) and analyses with the use of FlowJo 7.6.5 software (Tree Star, Ashland, OR).](pone.0227314.g001){#pone.0227314.g001}

NK cell-mediated cytotoxicity is impaired in patients with ALL {#sec011}
--------------------------------------------------------------

An impaired NK cell effector functions has been associated with a higher incidence of cancer including hematological malignancies \[[@pone.0227314.ref037], [@pone.0227314.ref038]\]. There are few studies assessing the functional competence of NK cells in pediatric patients with ALL. The observation by Rouce and collaborators has provided information on the state of NK cell responsiveness at moment of diagnosis and remission \[[@pone.0227314.ref020]\]. However, none study has provided information on whether NK cell-mediated cytotoxicity results equally affected taking in consideration important prognostic features and risk factors. Our data showed, as evidenced by degranulation assays using K562 as target cells, that peripheral blood NK cells from ALL patients have an impaired NK cell cytotoxicity compared to age matched-controls ([Fig 2A and 2B](#pone.0227314.g002){ref-type="fig"}). The impaired NK cell-mediated lysis of K562 was more significantly affected in those patients suffering from T-ALL compared to B-ALL ([Fig 2C](#pone.0227314.g002){ref-type="fig"}). Interestingly, those pediatric ALL patients with ages above 10 years showed a significant lower NK cell degranulation compared to patients with ages between 1- and 9-year-old ([Fig 2D](#pone.0227314.g002){ref-type="fig"}). Moreover, in those patients stratified into a high-risk population, the NK cell degranulation was significantly reduced compared to standard-risk population to compared to age-matched controls ([Fig 2E](#pone.0227314.g002){ref-type="fig"}). Interestingly, NK cell cytotoxicity was compromised in those B-ALL patients with WBC over 50,000xmm3 compared to B-ALL patients with WBC below 50,000xmm3 ([Fig 2F](#pone.0227314.g002){ref-type="fig"}). These data suggest that NK cell cytotoxicity is not equally affected in all pediatric patients suffering with ALL.

![NK cell-mediated cytotoxicity is impaired in patients with ALL.\
A) Representative FACS plots depict NK cell response (CD107a degranulation) against K562 cells. B) NK cell degranulation assays were performed in 41 acute leukemia patients and 14 healthy age-matched controls. C) NK cell degranulation assays were performed in 30 pre-B-ALL, 6 T-ALL patients and 14 age-matched controls. D) NK cell degranulation was analyzed according to age in 30 pre-B-ALL patients and 14 age-matched controls. E) NK cell degranulation was analyzed according to high risk or standard risk in 30 pre-B-ALL patients and 14 age-matched controls. F) NK cell degranulation was analyzed according to WBC in 30 pre-B-ALL patients and 14 age-matched controls. Degranulation was represented as ΔCD107a, which is the difference between the percentage of NK cells expressing surface CD107a after K562 stimulation and the percentage of NK cells expressing surface CD107a after incubation with medium alone. Error bars denote standard error of the mean between individuals within group. P values report significance according to U-Mann Whitney Test one-tail.](pone.0227314.g002){#pone.0227314.g002}

SAP expression in NK cells from B-ALL patients is partially reduced {#sec012}
-------------------------------------------------------------------

SAP has been reported to be critical in regulating NK cell responsiveness towards hematopoietic cells \[[@pone.0227314.ref026], [@pone.0227314.ref029]\]. Various mouse models indicate that NK cells lacking SAP expression loss the ability to kill hematopoietic cells whereas retain their competence to eliminate non-hematopoietic cells. In humans, SAP deficiency as consequence of deleterious mutations in *SH2D1A* results in an immunodeficiency characterized by an abnormal susceptibility to EBV infections. As consequence, lymphoproliferative disorders are observed in these patients probably caused by inability of NK cells to properly eliminate transformed cells and/or antigen presenting cells. Despite the importance of SAP in regulating NK cells effector functions, no other human pathology has been associated with SAP abnormal expression or function. As SAP plays a critical role in regulate NK cell responsiveness towards hematopoietic cells, we decided to evaluate whether SAP expression is abnormal in NK cells from patients suffering ALL leukemia at moment of diagnosis. Our data indicate that there is not a significant difference in the frequencies of NK cells expressing SAP between B-ALL patients and age-matched controls ([Fig 3A and 3B](#pone.0227314.g003){ref-type="fig"}). Moreover, the frequencies of NK cells expressing SAP remain normal when patients were stratified according to various prognostic features and risk factors ([Fig 3C--3E](#pone.0227314.g003){ref-type="fig"}). Although we did observe a significant difference only in patients with standard-risk compared to healthy controls, we did not observe any difference when healthy donors were compared to those ALL patients in high-risk group. These results suggest that the frequencies of NK cells expressing SAP remain unaffected in patients with B-ALL.

![Frequencies of NK cells expressing SAP are normal in patients with B-ALL.\
A) Representative FACS plots depict frequencies of SAP+ NK cells. B) Frequencies of CD3^-^CD56^+^ cells expressing SAP were analyzed in 18 pre-B-ALL patients compared to 14 age-matched controls. C) Frequencies of CD3-CD56+ cells expressing SAP were analyzed according to risk factor in 18 pre-B-ALL patients and 14 age-matched controls. D) Frequencies of CD3^-^CD56^+^ cells expressing SAP were analyzed according to age in 18 pre-B-ALL patients and 14 age-matched controls. E) Frequencies of CD3^-^CD56^+^ cells expressing SAP were analyzed according to WBC in 18 pre-B-ALL patients and 14 age-matched controls. Error bars denote standard error of the mean between individuals within group. P values report significance according to U-Mann Whitney Test one-tail.](pone.0227314.g003){#pone.0227314.g003}

In addition to frequencies of NK cells expressing SAP, we decide to evaluate the mean fluorescence intensity (MFI) of SAP in NK cells. We did not find a significant difference in SAP expression in NK cells from healthy controls and pre-B ALL patients ([Fig 4A and 4B](#pone.0227314.g004){ref-type="fig"}) Moreover, when patients were stratified according to other prognostic factors (age or risk factor) none difference was found between patients and age-matched healthy controls ([Fig 4C and 4D](#pone.0227314.g004){ref-type="fig"}). In contrast, we found that NK cells from patients with WBC over 50,000xmm^3^ express less SAP compared to patients with WBC below 50,000xmm^3^ ([Fig 4E](#pone.0227314.g004){ref-type="fig"}).

![SAP expression is partially reduced in NK cells from B-ALL patients.\
A) Representative FACS histogram depict MFI of SAP+ NK cells. B) SAP fold MFI for CD3-CD56+ cells was analyzed in 18 pre-B-ALL patients regarding 14 age-matched controls. C) SAP fold MFI for CD3-CD56+ cells was analyzed according to risk factor in 18 pre-B-ALL patients and 14 age-matched controls. D) SAP fold MFI for CD3-CD56+ cells was analyzed according to age of 18 pre-B-ALL patients and 14 age-matched controls. E) SAP fold MFI for CD3-CD56+ cells was analyzed according to WBC in 18 pre-B-ALL patients. Error bars denote standard error of the mean between individuals within group. P values report significance according to U-Mann Whitney Test one-tail.](pone.0227314.g004){#pone.0227314.g004}

A positive correlation between SAP expression and a reduced NK cell cytotoxicity is revealed in B-ALL patients with WBC over 50,000xmm^3^ {#sec013}
-----------------------------------------------------------------------------------------------------------------------------------------

A reduction or absence of SAP expression results in a significant reduction in the ability of NK cells to kill malignant hematopoietic cells as evidenced in NK cells from patients with XLP1 \[[@pone.0227314.ref029], [@pone.0227314.ref039], [@pone.0227314.ref040]\]. Therefore, we determined whether a reduction in the expression of SAP observed in those patients with WBC over 50,000 correlates with an impaired NK cell-mediated cytotoxicity. By using a lineal regression analysis, our data demonstrated a positive correlation between a low expression of SAP and a reduced NK cell cytotoxicity in pediatric patients suffering from B-ALL ([Fig 5](#pone.0227314.g005){ref-type="fig"}).

![A positive correlation between SAP expression and a reduced NK cell cytotoxicity is revealed in B-ALL patients with WBC over 50,000xmm^3^.\
A positive correlation study was applied to 18 pre-B-ALL patients, where was possible to determine both NK cell-mediated cytotoxicity and SAP analysis expression. The R^2^- and P values are indicated.](pone.0227314.g005){#pone.0227314.g005}

Discussion {#sec014}
==========

Acute lymphoblastic leukemia represents the most common and lethal cancer during childhood \[[@pone.0227314.ref041], [@pone.0227314.ref042]\]. Whereas genetic and environmental factors are important factors that predispose the outcome, immune cells are now being recognized as determinants in the development of leukemia and other cancers. Among immune cells, NK cells play an important role in recognizing and killing leukemia cells \[[@pone.0227314.ref022], [@pone.0227314.ref038]\]. In consequence, NK cell-based immunotherapies have proven to be successful in the treatment of high-risk leukemia \[[@pone.0227314.ref038], [@pone.0227314.ref043]\]. However, it is also noticed that not all leukemias, either myeloid or lymphoid, are equally susceptible to these cell-based therapy regimens. Therefore, a phenotypic and functional characterization of NK cells under specific leukemia scenarios become essential in order to understand the particularities related to NK cells and different kinds of leukemia.

In this work, we presented a phenotypical and functional characterization of peripheral blood NK cells from pediatric patients suffering from ALL at moment of diagnosis. As shown by previous studies, we did observe a significant difference in the percentages of peripheral blood NK cells from patients at moment of diagnosis compared to healthy age-matched controls \[[@pone.0227314.ref035], [@pone.0227314.ref036]\]. This was also true when NK cell percentages were analyzed taking into consideration prognostic features such as WBC and whether leukemia was from T or B cell-type. Notably, a significant reduction in percentages of NK cells was also noticed when patients were stratified according to age, whereby those aged between 1 to 9 years display lower percentages of NK cells compared to patients aged 10 years old and above. As far as we know, our study is the first study conducted in patients from Mexico City, which have one of the highest risk factors for developing ALL worldwide.

Similar to results obtained by Rouce and colleagues, NK cell-mediated cytotoxicity towards K562 cells was reduced in peripheral blood NK cells from ALL leukemia patients compared to age-matches controls. This impaired NK cell-mediated cytotoxicity was observed in patients with both B-ALL and T-ALL. Interestingly, when NK cell-mediated lysis towards K562 was analyzed taking into consideration different prognostic features, an impaired NK cell-mediated cytotoxicity was observed only in patients classified as high- but not as low-risk compared to age-matched healthy controls. Interestingly, a lower NK cell-mediated cytotoxicity was also noticed in ALL patients aged over 10 years old and above compared to both healthy controls of same age, and to ALL patients aged between 1--9 years old. In contrast, ALL patients in the 1-9-year cohort did not display a lower NK cell-mediated cytotoxicity compared to age-matched healthy controls. Finally, an impaired NK cell-mediated cytotoxicity was also observed in those B-ALL patients with WBC over 50,000xmm3 compared to B-ALL patients with WBC below 50,000xmm3. These data suggest that an abnormal NK cell effector function is not necessarily equally observed in all pediatric B-ALL patients and that there are other factors that may contribute to determine whether the NK cell-mediated cytotoxicity will result impaired or not. According to our data, the WBC and patients age, resulted to be the major factors that were associated with an abnormal NK cell-mediated cytotoxicity. Interestingly, both WBC over 50,000xmm3 and age, are two reliable prognostic factors used to determine the risk factor and the probability of remission \[[@pone.0227314.ref002], [@pone.0227314.ref044]\]. Based on these findings, our study suggest that an impaired NK cell mediated cytotoxicity can also emerge as a possible prognostic factor for high risk pediatric patients suffering from B-ALL, complementing observations made by Agnieszka et al \[[@pone.0227314.ref045]\].

Minimal residual disease (MDR) has recently been describe as a reliable factor to determine risk factor and the probability of remission for ALL patients. In our study, we lack any information regarding the status for MRD in our patients, however it will be interesting to evaluate in further studies a possible association between an abnormal NK cell-mediated cytotoxicity and MRD. In addition, in only 17.7% of ALL patients from Mexico City, the four most common gene rearrangements have been detected \[[@pone.0227314.ref014], [@pone.0227314.ref046]\], making difficult to address how NK cell function may be affected by such genetic alterations in patients with ALL. With no doubt, this remain an interesting issue to be addressed in future studies.

The finding that those patients with WBC over 50,000xmm3 displayed a reduced NK cell lysis towards K562 at moment of diagnosis, suggest an important association between a compromised NK cell effector function and high probability of re-incidence of the disease. However, at this point, it is not clear why not all B-ALL patients displayed a significant reduction in the ability of NK cells to kill target cells and further studies will be necessary to address this issue.

SAP family adapters play an essential role in regulate NK cells lysis towards hematopoietic cells. Individuals carrying missense mutations in the gene encoding for SAP, develop a lymphoproliferative syndrome as consequence of an abnormal susceptibility of EBV infections \[[@pone.0227314.ref047], [@pone.0227314.ref048]\] and very often, these individuals develop lymphoma. Besides XLP-1, there are no other evidences where an abnormal SAP expression or function is associated with a human pathology. As far as we know, our study is the first evidence that in those pediatric B-ALL patients with WBC over 50,000xmm3, the NK cells display a partial decrease in SAP expression regarding those patients with WBC below 50,000xmm3. Moreover, by using a lineal regression analysis, our data demonstrated a positive correlation between a low expression of SAP and a reduced NK cell cytotoxicity in pediatric patients suffering from B-ALL. Therefore, our data suggest that a partial decrease in SAP expression may contribute with an impaired NK cell-mediated cytotoxicity observed in B-ALL patients. Our study also provide evidence that an abnormal NK cell phenotype and function are not equally displayed in pediatric patients suffering from B-ALL. These data suggest that there are unidentified factors that might contribute to influence NK cell biology in patients with leukemia. In contrast, NK cell mediated-cytotoxicity and SAP expression become important variables that might be useful to determine the patient outcome.

Conclusions {#sec015}
===========

In the present study it was observed that NK cells from children with ALL harbor an impaired cytotoxicity towards K562 at moment of diagnosis. A more detailed analysis taking into consideration prognostic features and risk factor, revealed that NK cell phenotype and function are not equally affected in all B-ALL patients. Moreover, NK cell-mediated cytotoxicity was compromised in those patients with a leukocyte count ≥50,000xmm3 where also it was found a decreased expression of SAP regarding patients with a leukocyte count \< 50,000xmm3. These data suggest a positive correlation between low SAP expression and decreased NK cell-mediated cytotoxicity in pediatric patients suffering from ALL.

10.1371/journal.pone.0227314.r001
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Reviewer \#1: The presence of NK cells in the bone marrow at diagnosis can be a prognostic factor in children with ALL (doi: 10.1155/2019/3596983). In the submitted work, Valenzuela-Vazquez and collogues proposed a phenotypical and functional characterization of NK cells in children with ALL comparing them to age-matched healthy donors. According to the opinion of this reviewer, the work turns out to be superficial both in terms of phenotypic characterization of NK cells (analyzed only as CD56+) and their functional characterization. Moreover, the low number of donors (N=8 compared to N=41 pts) and the fact that the groups of patients to be compared are unbalanced and under-represented (see T ALL (N=6) and ALL\> 50000/mm3 (N=4)) do not allow authors to reach statistical conclusions.

Major points

\- Enlarge the number of healthy donors and patients.

\- For the cytotoxic and degranulation assays, at least three serial dilutions have to be performed to evaluate NK activity. We suggest aliquots of 100 μl from each NK cell serial dilution containing 2 x 105, 1 x 105 and 0.5 x 105 cells, in triplicates, and aliquots of 100 μl of target cells (1 x 105cells/well) to be added to generate 2:1, 1:1 and 0.5:1 effector---to-target ratio (E:T ratio). In fact, cytotoxicity is more effective at higher E/T ratios, while degranulation responses are stronger at low E/T ratios.

\- Together with the frequency (percentage) of NK cells, please report their absolute number.

\- In Figure 1B, indicate the p value comparing ALL 10+ and ALL 1-9 that could be the most interesting results you obtained. Eliminate HD or increase their number. Eliminate the comparison between ALL \<50000 and \>50000 for the same reason.

\- Why in figure 2C there is less ALL 1-9 than in figure 1? It could be interesting to understand if they are less numerous compare to ALL 10+ (Fig1B) but more functional.

\- Since the paper seeks to clarify why in the Mexican population there is a higher frequency of high-risk relapsing patients and find new risk factors, according to this reviewer opinion, a gene expression analysis, or at least the analysis of NKG2D ligands, could improve the findings of this work and let to more interesting conclusions.

Minor points

\- Elimination of leukemia cells relies mainly on their recognition by both T cells and NK cells. Please revise the statement "NK cells are unique lymphocytes that seem to dominate the immune response against leukemia", otherwise justify it with proper citations from literature.

\- Please specify the type of samples collected and the number of cases analyzed (healthy age-matched controls and patients) in the Abstract and in the "Material and Methods" paragraph.

\- To estimate the degranulation of NK cells using anti-CD107a mAb, GolgiStop has to be added. Did you? Please clarify the protocol used.

\- SAP evaluation in NK cells is innovative. However, according to this reviewer opinion, to see differences among the groups analyzed, the analysis has to be revised indicating the frequency of SAP expressing NK cells and not the expression of SAP inside the NK cell gate.

\- In the figure1 legend, correct CD65 with CD56.

\- Are they only B-ALL patients in figure3 and 4 as described in the text?

\- Why adverse cytogenetic abnormalities have not been considered as risk factors?

\- Please better describe the FACS gating strategy. Pay attention to define NK cells as CD56+ cells among CD3- lymphocytes. Specify if and how you discriminate between progenitors and mature lymphocytes. Please show the gating strategy and the representative FACS dot plots/histograms in each figure.

\- Figure 1 A. Since T ALL are under represented compared to B ALL, I suggest not to separate B and T ALL.

\- In figure 2, correct the legend of the Y-axes: CD107a+ in CD56+CD3- cells. Calculate and report also the number of CD107a+ NK.

\- In figure 3, correct the legend of the Y-axes: SAP+ in CD56+CD3- (NK) cells. Calculate also the number of SAP+ NK that could be more informative.

\- Figure 5. The statistic is missing.

Reviewer \#2: In this study, Valenzuela-Vazquez and collegues have tested NK cell function (degranulation) and expression of SAP in a cohort of 41 pediatric acute leukemia patients in Mexico city. The study cohort is potentially interesting, as it is known that hispanic children have a higher incidence of ALL than non-hispanic children. The study is quite limited in that only degranulation and SAP expression is monitored, but it provides a nice addition to reports on the contribution of NK cells in pediatric ALL patients, for where there are still very few reports.

My main comments are:

\- In the introduction you can also comment on the study by de Smith et al in Blood (2014) where they found a correlation between a KIR A haplotype and leukemia risk in hispanic children, this is very relevant information for the current study.

\- Materials and methods: Please state the volume of blood drawn, and also include in this section information on the number of patients and healthy controls (even though this is stated in the Results section, it should also be included here).

-Please provide the suplier of the anitbodies used in this study.

\- Please explain what is meant by \"fold MFI\"; is it MFI of SAP in stained samples vs isotype controls? Also MFI is several places misspelled as MIF.

\- For degranulation, please clarify how deltaCD107a is calculated; is it the difference between CD107a measured against targets vs NK cells without targets?

\- Also clarify in the materials and methods the gating strategy used. For instance on line 255, it is written that a gate was set on CD3+ lymphocytes, did the atuhors mean to say \"CD3- lymphocytes\"? I assume that the authors have gated cells as CD3-CD56+ throughout the manuscript?

\- In the results section, the text describing panel 2C and 2D has been mixed up.

\- The figure describing impact of age on NK cell degranulation is missing several data points, please explain why or add the missing data points.

\- The authors report that high WBC translate into poor degranulation; can the authors discuss whether this also can be the by lower numbers of NK cells in the PBMC sample that can result in sub-optimal assay?

\- I suggest to merge figure 3 and 4 into one figure, and take out the graphs showing boys/girls as there is no difference between different sexes. Also write on the y-axis \"%SAP+ NK cells\", instead of \"% NK SAP+\".

\- In Figure 3 and 4 there are 18 data points, not 35 data points as stated in the figure legends, please modify.

\- Figure legends can be shortened, do not need to repeat methods, they are allready in the materials and methods section.

\- The text for Figure 4 does not match the actual figure, please modify.

\- Figure 5: Please provide r, and the p-value.

\- There are many grammatical and tyopgraphical errors in the manuscript, and I suggest that the authors cirtically re-read the text and correct these. For instance, write \"compared to\" instead of \"regarding\".

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227314.r002

Author response to Decision Letter 0

20 Nov 2019

Professor Joerg Heber

Editor-in-Chief

Plos One

Dear Dr. Heber:

You will find enclosed the revised version of manuscript PONE-D-19-20648, which we would like considered for publication in PlosOne.

We are pleased that the Editors and Reviewers were very supportive of our manuscript. As requested, we have addressed the queries of the Reviewers, by adding additional data and clarifications in the text. The corresponding changes in the text are highlighted in yellow. As a result of these various changes, we believe that the manuscript is much improved. We have also modified the manuscript according to the PlosOne format instructions and publication policies.

Below is a point-by-point response to the Reviewers' comments.

Major Points

Reviewer \#1:

1\. Enlarge the number of healthy donors and patients.

We agree with reviewer that the number of controls and patients is unbalanced. In order to improve the number of healthy controls analyzed, we have included 6 more age-matched healthy controls to the study. However, it is important to mention that statistical conclusions are possible taking into account that with the sample size analyzed of cases and controls, the differences observed were statistically significant with an adequate statistical power. Considering the sample size here analyzed, if the pooled variance would have been so small as 5 or so high as 20; therefore, the sample size used has a power to detect differences of 5% among the groups with a power of 94.38%. If the difference between the two groups would have been 10% or higher, the power to detect differences is of 100%. In the case of analyses of subgroups with 8 patients, differences of 5% and a pooled variance of 5% too, the statistical power was of 98.8%. For differences of 7% among subgroups, the power was of 100%. When we compared subgroups of 5 patients with differences of 5% among groups and the pooled variance was 5% too, the power was of 89.75%. When a differences of 10% was observed, the statistical power was of 100%.

On the other hand, it is important to mention that a lower number of controls is not an impediment for made comparisons between cases and controls. Although we agree that the inclusion of more controls could enhance the statistical power, the associations remained statistically significant after the inclusion of more controls.

2\. For the cytotoxic and degranulation assays, at least three serial dilutions have to be performed to evaluate NK activity. We suggest aliquots of 100 μl from each NK cell serial dilution containing 2 x 105, 1 x 105 and 0.5 x 105 cells, in triplicates, and aliquots of 100 μl of target cells (1 x 105cells/well) to be added to generate 2:1, 1:1 and 0.5:1 effector---to-target ratio (E:T ratio). In fact, cytotoxicity is more effective at higher E/T ratios, while degranulation responses are stronger at low E/T ratios.

We concur with the Reviewer that cytotoxic assays are also informative in evaluating NK cell function, however the paucity of peripheral blood available from each patient it makes difficult to performed both assays (specific lysis and degranulation assays) in all samples. Moreover, degranulation assays is a well-known standard method that allow to assess NK cell-mediated cytotoxicity and this method is broadly used not only in basic approaches to assess NK cell function but also for diagnosis of pathologies related to an abnormal NK cell function. We have included the proper references in Materials and methods.

3\. Together with the frequency (percentage) of NK cells, please report their absolute number.

We agree with reviewer that this is an important information, unfortunately this information was not available for all samples.

4\. In Figure 1B, indicate the p value comparing ALL 10+ and ALL 1-9 that could be the most interesting results you obtained. Eliminate HD or increase their number. Eliminate the comparison between ALL \<50000 and \>50000 for the same reason.

The requested p value has been indicated in revised Figure 1. In addition, we have increased the number of HC as suggested. The comparison between ALL \<50000 and \>50000 has been eliminated in the new figure 1 as requested.

5\. Why in figure 2C there is less ALL 1-9 than in figure 1? It could be interesting to understand if they are less numerous compare to ALL 10+ (Fig1B) but more functional.

This is an excellent point. This information has been corrected accordingly. These data are mentioned on p. 13, lines 298-300 and p. 15, lines 325-327

6\. Since the paper seeks to clarify why in the Mexican population there is a higher frequency of high-risk relapsing patients and find new risk factors, according to this reviewer opinion, a gene expression analysis, or at least the analysis of NKG2D ligands, could improve the findings of this work and let to more interesting conclusions.

We agree that a gene expression analysis, or at least the analysis of NKG2D ligands, could improve the findings of this work, however we considered that the gene expression analysis was not the scope of this manuscript or it will be part of other manuscript.

Minor Points

7\. Elimination of leukemia cells relies mainly on their recognition by both T cells and NK cells. Please revise the statement "NK cells are unique lymphocytes that seem to dominate the immune response against leukemia", otherwise justify it with proper citations from literature.

We agree with the reviewer; the statement has been modified accordingly throughout the text.

8\. Please specify the type of samples collected and the number of cases analyzed (healthy age-matched controls and patients) in the Abstract and in the "Material and Methods" paragraph.

We have included this information in the revised manuscript as requested by the reviewer. This information is mentioned on p. 4, lines 83-84, and p.4, lines 87-88.

9\. To estimate the degranulation of NK cells using anti-CD107a mAb, GolgiStop has to be added. Did you? Please clarify the protocol used.

We agree with the reviewer that the addition of GolgiStop is included in some protocols, however there are other that not include the use of GolgiStop, as is in this case. This information has been clarified in Materials and Methods. In addition, the proper references have been included.

10\. SAP evaluation in NK cells is innovative. However, according to this reviewer opinion, to see differences among the groups analyzed, the analysis has to be revised indicating the frequency of SAP expressing NK cells and not the expression of SAP inside the NK cell gate.

This point was included in the analysis as suggested by reviewer.

11\. In the figure 1 legend, correct CD65 with CD56.

This was corrected in the text as indicated.

12\. Are they only B-ALL patients in figure 3 and 4 as described in the text?

For figures 3 and 4 only B-ALL patients were included as indicated in the text.

13\. - Why adverse cytogenetic abnormalities have not been considered as risk factors?

This is an excellent point; however, gene rearrangements are found in only 17.7% of the patients with acute lymphoblastic leukemia from Mexico City. This information has been included in the discussion to clarified the point indicated by the reviewer. p. 21, lines 466-469.

14\. Please better describe the FACS gating strategy. Pay attention to define NK cells as CD56+ cells among CD3- lymphocytes. Specify if and how you discriminate between progenitors and mature lymphocytes.

We have better described these points in the revised manuscript as indicated by the reviewer. Since all analysis were performed in mononuclear cells form peripheral blood, we did not discriminate between progenitors and mature lymphocytes.

15\. Please show the gating strategy and the representative FACS dot plots/histograms in each figure.

A representative FACS plots/histogram has been included in each figure as suggested by the reviewer.

16\. Figure 1 A. Since T ALL are underrepresented compared to B ALL, I suggest not to separate B and T ALL.

This is an important suggestion, however we think that data is important as this information has not been published previously.

17\. In figure 2, correct the legend of the Y-axes: CD107a+ in CD56+CD3- cells. Calculate and report also the number of CD107a+ NK.

The legend has been corrected as suggested by the reviewer. Unfortunately, we did not analyze the absolute number of NK cells in this study or this information was not available for all samples.

18\. In figure 3, correct the legend of the Y-axes: SAP+ in CD56+CD3- (NK) cells. Calculate also the number of SAP+ NK that could be more informative.

The legend has been corrected as suggested by the reviewer. Unfortunately, we did not analyze the absolute number of NK cells in this study, or this information was not available for all samples.

19\. Figure 5. The statistic is missing.

The statistic has been incorporated in corresponding figure as indicated by reviewer.

Reviewer \#2:

1\. In the introduction you can also comment on the study by de Smith et al in Blood (2014) where they found a correlation between a KIR A haplotype and leukemia risk in hispanic children, this is very relevant information for the current study.

This is an excellent point. The study referred by the reviewer has been commented in the introduction as indicated in p. 8, lines 173-175.

2\. Materials and methods: Please state the volume of blood drawn, and also include in this section information on the number of patients and healthy controls (even though this is stated in the Results section, it should also be included here).

We have included this information as requested by reviewer.

3\. Please provide the supplier of the antibodies used in this study.

This information has been included in Materials and Methods.

4\. Please explain what is meant by \"fold MFI\"; is it MFI of SAP in stained samples vs isotype controls? Also MFI is several places misspelled as MIF.

This information has been corrected.

5\. For degranulation, please clarify how deltaCD107a is calculated; is it the difference between CD107a measured against targets vs NK cells without targets?

This information has been clarified in Materials and Methods. See p. 12, lines 265-268

6\. Also clarify in the materials and methods the gating strategy used. For instance on line 255, it is written that a gate was set on CD3+ lymphocytes, did the authors mean to say \"CD3- lymphocytes\"? I assume that the authors have gated cells as CD3-CD56+ throughout the manuscript?

We appreciate this comment from reviewer. This point has been clarified in the Materials and Methods section.

7\. In the results section, the text describing panel 2C and 2D has been mixed up.

This point has been corrected accordingly.

8\. The figure describing impact of age on NK cell degranulation is missing several data points, please explain why or add the missing data points.

This point has been corrected.

9\. The authors report that high WBC translate into poor degranulation; can the authors discuss whether this also can be the by lower numbers of NK cells in the PBMC sample that can result in sub-optimal assay?

This is an excellent point by the reviewer. Whereas this possibility can not be formally excluded, we did not find a significant difference in the percentages of NK cells between patients with high or low WBC.

10\. I suggest to merge figure 3 and 4 into one figure, and take out the graphs showing boys/girls as there is no difference between different sexes. Also write on the y-axis \"%SAP+ NK cells\", instead of \"% NK SAP+\".

We appreciate the suggestions by the reviewer. The y-axis has been corrected, and graphs showing boys/girls has been eliminated. Merge of figures 3 and 4 was not possible since new data was incorporated as suggested by reviewer \#1.

11\. In Figure 3 and 4 there are 18 data points, not 35 data points as stated in the figure legends, please modify.

The legend has been modified accordingly.

12\. Figure legends can be shortened, do not need to repeat methods, they are already in the materials and methods section.

Figures legends were shortened as suggested by reviewer.

13\. The text for Figure 4 does not match the actual figure, please modify.

The Figure 4 and text has been corrected.

14\. Figure 5: Please provide r, and the p-value.

These values have been incorporated in figure 5.

15\. There are many grammatical and typographical errors in the manuscript, and I suggest that the authors critically re-read the text and correct these. For instance, write \"compared to\" instead of \"regarding\".

We appreciate the comments by the reviewer. Grammatical and typographical errors have been revised and corrected.
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Click here for additional data file.
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Decision Letter 1

Bertolini

Francesco

Academic Editor

© 2020 Francesco Bertolini

2020

Francesco Bertolini

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

3 Dec 2019

PONE-D-19-20648R1

Functional characterization of NK cells in Mexican pediatric patients with acute lymphoblastic leukemia: Report from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia.

PLOS ONE

Dear Dr Cruz-Munoz,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process by Reviewer \#1.

We would appreciate receiving your revised manuscript by Jan 17 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Francesco Bertolini, MD, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I thanks Authors for accurately correct the manuscript answering all the questions.

Some suggestions:

Minor

line 302 please use \"lower\" instead of \"abnormal\".

line 305 percentages of nk cell in the lymphocyte gates.

Fig 2 c, d, e. You can appreciate two clusters. Please be sure that data are correct and not due to acquisition byass. Same day of acquisition?

Major

line 368 \"significant difference\" it is right but p value is 0.0468. Please pay attention to not overestimate data and conclusions.

line 450 \"severe impaired nk cytotoxicity\" is not a correct definition. p value is 0.02 and sample size is little and this could bring to uncertain conclusions. The same at line 499, please eliminate \"severely\".

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227314.r004

Author response to Decision Letter 1

10 Dec 2019

December 5, 2019

Professor Joerg Heber

Editor-in-Chief

Plos One

Dear Dr. Heber:

You will find enclosed the revised version of manuscript PONE-D-19-20648, which we would like considered for publication in Plos One.

We are very pleased that the Editors and Reviewers were very supportive of our manuscript. As requested, we have addressed the queries of the Reviewer \#1, by doing clarifications in the text. The corresponding changes in the text are highlighted in yellow. As a result of these changes, we believe that the manuscript is improved. We have also modified the manuscript according to the PlosOne format instructions and publication policies.

Below is a point-by-point response to the comments of the Reviewer \#1.

Reviewer \#1:

Minor suggestions

1\. line 302 please use \"lower\" instead of \"abnormal\"

We have use lower instead of abnormal in the corresponding line.

2\. line 305 percentages of nk cell in the lymphocyte gates.

We have included in the text the suggestion made by the reviewer.

3\. Fig 2 c, d, e. You can appreciate two clusters. Please be sure that data are correct and not due to acquisition byass. Same day of acquisition?

This is an interesting point. We agree with the reviewer that two cluster can be observed in some graphics, however we have checked all data and we are certainly that information is correct and no due to acquisition artefacts. We did not acquire all samples the same day. To ensure the reliability of our results for immunophenotyping and functional assays, all experiments were analyzed in a flow cytometer FACS ARIA III (BD) with a biannual maintenance, inspection and correction service. Additionally, the quality of measures is sustained by daily quality controls monitoring overall flow cytometric performance (laser alignment and fluorescence stability).

Major suggestions

4\. line 368 \"significant difference\" it is right but p value is 0.0468. Please pay attention to not overestimate data and conclusions.

We agree with the reviewer. We have put attention in order to not overestimate data and conclusions by modifying the respective phrase in the text.

"Although we did observe a significant difference only in patients with standard-risk compared to healthy controls, we did not observe any difference when healthy donors were compared to those ALL patients in high-risk group..."

5\. line 450 \"severe impaired nk cytotoxicity\" is not a correct definition. p value is 0.02 and sample size is little and this could bring to uncertain conclusions. The same at line 499, please eliminate \"severely\".

We agree with the reviewer. We have made the suggestions made by the reviewer by not using the word "severe" or "severely" throughout the text.

"Moreover, patients presenting a leukocyte count ≥ 50,000xmm3 displayed a severe reduction in NK-cell mediated cytotoxicity...."

"In addition, NK cell function was observed to be severely compromised in patients with a leukocyte count...."

"Interestingly, NK cell cytotoxicity was severely compromised in those B-ALL patients with WBC over...."

"Finally, a severe impaired NK cell-mediated cytotoxicity was also observed in those B-ALL patients with WBC over 50,000xmm3 compared to B-ALL patients with WBC below 50,000xmm3...."

"The finding that those patients with WBC over 50,000xmm3 displayed a severely reduced NK cell lysis towards K562...."

"Moreover, NK cell-mediated cytotoxicity was severely compromised in those patients with a leukocyte count ≥50,000xmm3 where also it was found a decreased expression of SAP regarding patients with a leukocyte count \< 50,000xmm3..."

We thank you and the Reviewers for your support and constructive comments. We hope that our revised in now suitable for publication in Plos One.

Sincerely,

Mario E. Cruz-Muñoz

Juan Manuel Mejía-Aranguré
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© 2020 Francesco Bertolini
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Francesco Bertolini

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

17 Dec 2019

Functional characterization of NK cells in Mexican pediatric patients with acute lymphoblastic leukemia: Report from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia.

PONE-D-19-20648R2

Dear Dr. Cruz-Munoz,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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